A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma

NCT ID: NCT05390528

Last Updated: 2023-08-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-20
• Study Completion Date: 2024-12-30

Brief Summary

A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in patients with locally advanced/metastatic solid tumors or lymphoma.Up to 150 patients will be included in this study. Up to 30 DLT evaluable patients will be enrolled in phase 1a (dose escalation), 40 per-protocol treated patients in phase 1b (dose expansion), and 80 per-protocol treated patients in phase 2. Phase 1a to evaluate safety, dose limiting toxicity (DLT), and the maximum tolerated dose (MTD) of HLX301 in patients with advanced or metastatic tumors who have failed or are intolerant to standard therapy, or for whom no standard therapy is available.Phase 1b to identify the recommended phase 2 dose (RP2D) of HLX301 in patients with advanced or metastatic NSCLC who have failed or are intolerant to standard therapy, or for whom no standard therapy is available.

Phase 2 to evaluate the anti-tumor activity of HLX301 in patients with histologically or cytologically-confirmed non-small cell lung cancer (NSCLC), gastric/esophagogastric junction adenocarcinoma (GC/EGJ), head and neck squamous cell carcinoma (HNSCC), or urothelial carcinoma (UC) tumors that express PD-L1, after one or two prior systemic treatments and without standard therapy。

Conditions

Advanced Tumors; Lymphoma; Metastatic Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental Group(phase Ia)

Phase 1a uses accelerated titration design and Bayesian optimal interval (BOIN) design to investigate the safety of HLX301 and determine MTD.Six dose levels of 0.25 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 20mg/kg are planned for dose finding.

Group Type: EXPERIMENTAL

HLX301

Intervention Type: DRUG

HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.

Interventions

HLX301

HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.

Intervention Type: DRUG

Other Intervention Names

A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody

Eligibility Criteria

Inclusion Criteria

Subjects who meet each of the following criteria are eligible for inclusion:

1. Patients who meet the following criteria will be enrolled:

Phase 1a dose escalation: patients must have histologically or cytologically confirmed malignant solid tumors which are advanced or metastatic, have failed prior standard treatment, and be intolerant or ineligible for standard therapy (with the exception of hepatocellular carcinoma, which meets diagnostic criteria by dynamic CT/MRI).

2. Age ≥ 18 years, or legally an adult as per local regulations.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

4. Measurable disease according to RECIST Version 1.1

5. Able to provide informed consent.

6. A life expectancy longer than three months.

7. Adequate hematologic parameters, defined as white blood cell count ≥ 3000/mm3 and absolute neutrophil counts ≥ 1500/mm3; hemoglobin≥9gm/dL; platelet count ≥ 90,000/mm3 without platelet transfusion within 14 days.

8. Adequate hepatic function, defined as serum albumin ≥ 3.0 g/dL; serum total bilirubin ≤ 1.5x upper limit of normal (ULN); serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN (AST and ALT ≤ 5 × ULN for patients with known liver metastasis or primary hepatocellular carcinoma); Child-Pugh score A in HCC.

9. Adequate renal function, defined as serum creatinine ≤ 1.5x upper limit of normal (ULN).

10. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 50% measured by cardiac ultrasound or MUGA scan; normal ECG or ECG without any clinically significant findings.

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study:

1. Received prior anti-TIGIT therapy.

2. Patients who still have persistent ≥ grade 2 toxicities from prior therapies.

3. Concurrent unstable or uncontrolled medical conditions including, but not limited to, the following:

i. Ongoing or active systemic infections requiring antibiotic treatment ii. Clinically significant arrhythmia, unstable angina pectoris, class III or IV congestive heart failure as per the New York Heart Association, or acute myocardial infarction in the past 6 months iii. Unhealed wound or ulcers persisting ≥ 3 months iv. Psychiatric illness or a social situation that would preclude study compliance v. Any other diseases, metabolic dysfunction, physical examination findings, or laboratory results raising reasonable suspicion of a disease or condition that contraindicates use of the investigational drug, that may affect interpretation of results, or that may place the patient at high risk of treatment complications.

4. Active CNS metastasis indicated by clinical symptoms, cerebral edema, steroid requirements (not including maintenance low dose steroids), or progressive growth.

5. History of any secondary malignancy in the past 2 years with the exception of curatively treated non-melanoma skin cancer or treated cervical carcinoma in situ.

6. Active or a history of (in the past 2 years) of autoimmune disease or syndrome requiring systemic steroid or immunosuppressive agents.

7. History of interstitial lung disease.

8. Hepatitis B virus infection (HBsAg or anti-HBc positive, and HBV-DNA positive), hepatitis C virus infection (anti-HCV positive, and HCV-RNA positive), or co-infection with hepatitis B and hepatitis C (positive HBsAg or anti-HBc, and positive anti-HCV).

9. Human immunodeficiency virus (HIV) infection.

10. Major surgery, treatment with anti-cancer or investigational agents, or radiotherapy in the 28 days prior to the first study dosing.

11. Treatment with immune check point inhibitors (anti-PD-1 or anti-PD-L1) in the 42 days prior to the first study dosing.

12. Pregnancy or breast-feeding.

13. Patients of reproductive age who are unable to use effective contraceptive measures in the period from the first dose of study drug to 180 days following the last dose of study drug. Female patients who have been amenorrheic for at least 12 months, have had a hysterectomy or oophorectomy, or have been surgically sterilized do not require contraception.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Henlius Biotech

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Jilin Provincial Cancer Hospital

Changchun, Jilin, China

Site Status: RECRUITING

Shandong Cancer Hospital

Jinan, Shandong, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Ying Cheng, Doctor

Role: primary

jl.cheng@163.com

0431-80596315

Yuping Sun, Doctor

Role: primary

13370582181@163.com

13370582181

Other Identifiers

HLX301-002

Identifier Type: -

Identifier Source: org_study_id